Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hyphens Pharma InternationalSGX:1J5 -2.70%82 EV-to-FCF is 5.18 as of Sep. 07, 2026, which is 46% below its 10-year median of 9.68. GuruFocus rates SGX:1J5 with a GF Score™ of 82/100 and a GF Value™ of S$0.31 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 71 Medical Distribution companies, Hyphens Pharma International ranks better than 90.14% on this metric.
The historical rank and industry rank for Hyphens Pharma International's EV-to-FCF or its related term are showing as below:
SGX:1J5'
s EV-to-FCF Range Over the Past 10 Years
Min: -35.9 Med: 9.68 Max: 29.73
Current: 5.18
During the past 11 years, the highest EV-to-FCF of Hyphens Pharma International was 29.73. The lowest was -35.90. And the median was 9.68.
SGX:1J5's EV-to-FCF is ranked better than 90.14% of 71
companies
in the Medical Distribution industry
Industry Median: 17.8
vs SGX:1J5: 5.18
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hyphens Pharma International (SGX:1J5) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hyphens Pharma International's PE Ratio (TTM) for today is calculated as:
Hyphens Pharma International's share price for today is S$0.36.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hyphens Pharma International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was S$0.027.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Hyphens Pharma International EV-to-FCF Related Terms
Hyphens Pharma International EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Hyphens Pharma International's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hyphens Pharma International EV-to-FCF vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Hyphens Pharma International's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Hyphens Pharma International's EV-to-FCF falls into.
Hyphens Pharma International's current Enterprise Value is S$99.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hyphens Pharma International's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was S$19.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hyphens Pharma International (SGX:1J5) has a EV-to-FCF of 5.18 as of Sep. 07, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hyphens Pharma International and its competitors. This is 46% below median its historical median of 9.68. According to the industry distribution chart, Hyphens Pharma International ranks #7 out of 71 companies in the Medical Distribution industry, placing it in the top 9.9%.
Is Hyphens Pharma International's EV-to-FCF too high?
Hyphens Pharma International's current EV-to-FCF of 5.18 is 46% below median its 10-year median of 9.68. The Medical Distribution industry median EV-to-FCF is 17.80. Hyphens Pharma International's value of 5.18 is 70.9% below this industry median. Based on the distribution chart, Hyphens Pharma International ranks #7 out of 71 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Hyphens Pharma International has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hyphens Pharma International's EV-to-FCF compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Hyphens Pharma International ranks #7 out of 71 companies for EV-to-FCF. This places Hyphens Pharma International in the top 10% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 17.80. Hyphens Pharma International's value of 5.18 is 70.9% below this benchmark. While the company's 10-year median is 9.68 vs. the industry median of 17.80, Hyphens Pharma International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Distribution company?
The median EV-to-FCF among Medical Distribution companies is 17.80, based on 71 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hyphens Pharma International's current EV-to-FCF of 5.18 is 70.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hyphens Pharma International and its competitors. For the Medical Distribution industry, the median EV-to-FCF is 17.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hyphens Pharma International's current EV-to-FCF is 5.18, which is 46% below median its own 10-year median of 9.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyphens Pharma International stock overvalued right now?
Based on GuruFocus' analysis, Hyphens Pharma International (SGX:1J5) is currently considered Modestly Overvalued. The stock's GF Value™ is S$0.31, compared to a current price of S$0.36 — trading 16.1% above its estimated fair value. The current EV-to-FCF is 5.18, which is 46% below median its 10-year median of 9.68 and 70.9% below the Medical Distribution industry median of 17.80. Hyphens Pharma International's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Hyphens Pharma International (SGX:1J5), the current EV-to-FCF is 5.18 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hyphens Pharma International (SGX:1J5) Overvalued in 2026?
Based on GuruFocus' analysis, Hyphens Pharma International stock appears to be overvalued.
The current stock price of S$0.36 is trading 16.1% above its estimated GF Value™ of S$0.31.
GuruFocus considers Hyphens Pharma International to be Modestly Overvalued.
Key valuation signals for SGX:1J5:
EV-to-FCF: 5.18 (46% below median its 10-year median of 9.68)
GF Value™: S$0.31 vs. price of S$0.36 (16.1% above fair value)
Industry Position: 70.9% below the Medical Distribution median (#7 of 71)
No single metric tells the full story. See the SGX:1J5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hyphens Pharma International Ltd is a pharmaceutical company. Its segments include the Pharmaceutical and Medical Aesthetics segment; Proprietary Brands segment; and Digital Platform and E-Pharmacy segment. The Pharmaceutical and Medical Aesthetics segment engages in the business of marketing and selling a range of pharmaceutical and medical aesthetics products with exclusivity in the relevant ASEAN countries. The Proprietary Brands segment develops, markets, and sells dermatological, pharmaceuticals and health supplement products. The Digital Platform and E-Pharmacy segment is a digital platform servicing procurement needs of healthcare professionals, healthcare institutions, and retail pharmacies, mainly in Singapore.
82GF Score
Get the complete analysis for SGX:1J5
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:1J5 has been successfully added to your 
